Abstract
Eisenmenger syndrome is associated with irreversible increase in pulmonary vascular resistance causing reduced survival. Bosentan, a non-selective endothelin receptor antagonist is the commonly used specific pulmonary arterial hypertension drug in Eisenmenger syndrome. In this paper, we present a case of recurrent gastrointestinal bleeding in a 23-year-old female with Eisenmenger syndrome who was only under bosentan treatment, which has not been reported previously. Most common adverse effect of bosentan is elevation in the liver enzymes however, bleeding complication is very rare. On the contrary, it was proposed that bosentan might be a potential protector against hyperacidity and mucosal erosion that occur as a consequence of stress. Although the mechanistic relationship of bleeding tendency and role of Eisenmenger syndrome concomitant with bosentan treatment is far from conclusive statement for now, this association warrants and should draw attention of clinicians and researches in this field.
Keywords: Bosentan, congenital heart disease, eisenmenger, gastrointestinal bleeding, pulmonary hypertension.
Current Drug Safety
Title:Recurrent Gastrointestinal Bleeding in a Patient with Eisenmenger Syndrome Using Bosentan
Volume: 8 Issue: 4
Author(s): Ibrahim Sari, Hakan Cam, M. Sait Dag, Erdal Durmus, Tarik Kivrak, Kursat Tigen and Vedat Davutoglu
Affiliation:
Keywords: Bosentan, congenital heart disease, eisenmenger, gastrointestinal bleeding, pulmonary hypertension.
Abstract: Eisenmenger syndrome is associated with irreversible increase in pulmonary vascular resistance causing reduced survival. Bosentan, a non-selective endothelin receptor antagonist is the commonly used specific pulmonary arterial hypertension drug in Eisenmenger syndrome. In this paper, we present a case of recurrent gastrointestinal bleeding in a 23-year-old female with Eisenmenger syndrome who was only under bosentan treatment, which has not been reported previously. Most common adverse effect of bosentan is elevation in the liver enzymes however, bleeding complication is very rare. On the contrary, it was proposed that bosentan might be a potential protector against hyperacidity and mucosal erosion that occur as a consequence of stress. Although the mechanistic relationship of bleeding tendency and role of Eisenmenger syndrome concomitant with bosentan treatment is far from conclusive statement for now, this association warrants and should draw attention of clinicians and researches in this field.
Export Options
About this article
Cite this article as:
Sari Ibrahim, Cam Hakan, Dag Sait M., Durmus Erdal, Kivrak Tarik, Tigen Kursat and Davutoglu Vedat, Recurrent Gastrointestinal Bleeding in a Patient with Eisenmenger Syndrome Using Bosentan, Current Drug Safety 2013; 8 (4) . https://dx.doi.org/10.2174/1574886319999990001
DOI https://dx.doi.org/10.2174/1574886319999990001 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Overview: Enzyme-catalyzed Enantioselective Biotransformation of Chiral Active Compounds Used in Hypertension Treatment
Current Organic Chemistry Vascular and Cellular Calcium in Normal and Hypertensive Pregnancy
Current Clinical Pharmacology Sleep Disturbances Due to Pulmonary Medications
Current Respiratory Medicine Reviews Epidural Labour Analgesia and Labour Outcome
Current Women`s Health Reviews Sleep Duration as a Risk Factor for Cardiovascular Disease- a Review of the Recent Literature
Current Cardiology Reviews Current and Emerging Treatments for Metastatic Renal Cell Carcinoma
Current Cancer Drug Targets FDG-PET Scanning Shows Distributed Changes in Cortical Activity Associated with Visual Hallucinations in Eye Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Renoprotection with Anti-Hypertensives: Reduction of Proteinuria and Improvement of Oxygenation via Inhibition of the Renin-Angiotensin System
Current Hypertension Reviews Oxidative Stress and Antioxidative Enzyme Activities in Chronic Kidney Disease and Different Types of Renal Replacement Therapy
Current Protein & Peptide Science Cooling the Injured Brain: How Does Moderate Hypothermia Influence the Pathophysiology of Traumatic Brain Injury
Current Pharmaceutical Design Pharmacogenetics in Methadone Therapy
Current Pharmacogenomics and Personalized Medicine Selective Neuronal Nitric Oxide Synthase Inhibitors
Current Topics in Medicinal Chemistry Silent Partner in Blood Vessel Homeostasis? Pervasive Role of Nitric Oxide in Vascular Disease
Current Hypertension Reviews Editorial [Hot Topic: Prebiotics and Probiotics: Delivering Therapeutics as Dietary Components (Executive Editor: Colum Dunne)]
Current Pharmaceutical Design Glaucoma and Aging
Current Aging Science Stroke Outcomes in Mice Lacking the Genes for Neuronal Heme Oxygenase-2 and Nitric Oxide Synthase
Current Neurovascular Research Kv1.5-Kvβ Interactions: Molecular Determinants and Pharmacological Consequences
Mini-Reviews in Medicinal Chemistry Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) During Pregnancy and the Risk for Autism spectrum disorder (ASD) and Attention deficit hyperactivity disorder (ADHD) in the Offspring: A True Effect or a Bias? A Systematic Review & Meta-Analysis
Current Neuropharmacology Cyclooxygenase-2 Inhibitors as a Therapeutic Target in Inflammatory Diseases
Current Medicinal Chemistry A More Accurate Approach to Molecular Genetics Analysis in Vascular Disease
Cardiovascular & Hematological Disorders-Drug Targets